Applications of visual evoked potentials and Fourier-domain optical coherence tomography in Parkinson's disease: a controlled study.
暂无分享,去创建一个
Lucas Barasnevicius Quagliato | Carolina Domingues | Elizabeth Maria Aparecida Barasnevicius Quagliato | Elvira Barbosa de Abreu | Newton Kara-Junior | N. Kara-Junior | E. Abreu | L. B. Quagliato | C. Domingues | E. B. Quagliato | N. Kara-Júnior | Newton Kara-Júnior
[1] R. Inzelberg,et al. Retinal nerve fiber layer thinning in Parkinson disease , 2004, Vision Research.
[2] G. Fénelon,et al. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. , 2000, Brain : a journal of neurology.
[3] A. Antal,et al. Primary Visual and Visuocognitive Deficits , 2013 .
[4] J. Kassubek,et al. Retinal single-layer analysis in Parkinsonian syndromes: an optical coherence tomography study , 2013, Journal of Neural Transmission.
[5] U. Mosimann,et al. Retinal thickness in Parkinson's disease. , 2011, Parkinsonism & related disorders.
[6] I. Bodis-Wollner,et al. Inner retinal layer thinning in Parkinson disease. , 2009, Archives of ophthalmology.
[7] A. Schnitzler,et al. Optical Coherence Tomography in Parkinsonian Syndromes , 2012, PloS one.
[8] M. Repka,et al. Ocular motor and sensory function in Parkinson's disease. , 2012, Ophthalmology.
[9] Lees Aj,et al. Parkinson's Disease Society Brain Bank, London: overview and research. , 1993 .
[10] H. Kolb,et al. The synaptic organization of the dopaminergic amacrine cell in the cat retina , 1990, Journal of neurocytology.
[11] M. Yahr,et al. Measurements of visual evoked potentials in Parkinson's disease. , 1978, Brain : a journal of neurology.
[12] A. Antal,et al. Visuo-cognitive dysfunctions in Parkinson's disease. , 1998, Clinical neuroscience.
[13] I. Bodis-Wollner. Visual deficits related to dopamine deficiency in experimental animals and Parkinson's disease patients , 1990, Trends in Neurosciences.
[14] D Regan,et al. Low-contrast letter charts in early diabetic retinopathy, ocular hypertension, glaucoma, and Parkinson's disease. , 1984, The British journal of ophthalmology.
[15] A. Lang,et al. Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers , 2011, Neurology.
[16] T. Di Paolo,et al. Decreased dopamine in the retinas of patients with Parkinson's disease. , 1990, Investigative ophthalmology & visual science.
[17] Hansjürgen Bratzke,et al. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages) , 2002, Journal of Neurology.
[18] Y. Çağlar,et al. Correlation between retinal morphological and functional findings and clinical severity in Parkinson’s disease , 2008, Documenta Ophthalmologica.
[19] A. Lees,et al. Parkinson's Disease Society Brain Bank, London: overview and research. , 1993, Journal of neural transmission. Supplementum.
[20] A. Mariani,et al. Amacrine cells of the rhesus monkey retina , 1990, The Journal of comparative neurology.
[21] C. Tranchant. Parkinson's disease and nonmotor dysfunction , 2006 .
[22] C. Nicholson,et al. Extracellular dopamine concentration in the retina of the clawed frog, Xenopus laevis. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[23] M. Ghilardi,et al. Visual evoked potentials in parkinsonism and dopamine blockade reveal a stimulus-dependent dopamine function in humans. , 1986, Journal of neurology, neurosurgery, and psychiatry.
[24] O. Blin,et al. Dopaminergic modulation of visual sensitivity in man , 1993, Fundamental & clinical pharmacology.
[25] M. Moschos,et al. Morphologic Changes and Functional Retinal Impairment in Patients with Parkinson Disease without Visual Loss , 2011, European journal of ophthalmology.
[26] A. Lang,et al. Parkinson's disease. First of two parts. , 1998, The New England journal of medicine.